Charles Schwab’s Seres Therapeutics MCRB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $245K | Sell |
31,049
-581
| -2% | -$4.42K | ﹤0.01% | 3354 |
|
|
2026
Q1 | $281K | Buy |
31,630
+261
| +0.8% | +$3.06K | ﹤0.01% | 3254 |
|
|
2025
Q4 | $467K | Sell |
31,369
-34
| -0.1% | -$593 | ﹤0.01% | 3177 |
|
|
2025
Q3 | $604K | Sell |
31,403
-3,473
| -10% | -$55.4K | ﹤0.01% | 3118 |
|
|
2025
Q2 | $387K | Sell |
34,876
-6,829
| -16% | -$60.1K | ﹤0.01% | 3226 |
|
|
2025
Q1 | $584K | Sell |
41,705
-1,586
| -4% | -$24.8K | ﹤0.01% | 3022 |
|
|
2024
Q4 | $720K | Buy |
43,291
+5,855
| +16% | +$95.1K | ﹤0.01% | 3028 |
|
|
2024
Q3 | $708K | Buy |
37,436
+11,139
| +42% | +$226K | ﹤0.01% | 3032 |
|
|
2024
Q2 | $381K | Sell |
26,297
-11,069
| -30% | -$185K | ﹤0.01% | 3298 |
|
|
2024
Q1 | $578K | Buy |
37,366
+3,547
| +10% | +$76.5K | ﹤0.01% | 2969 |
|
|
2023
Q4 | $947K | Sell |
33,819
-4,009
| -11% | -$105K | ﹤0.01% | 2851 |
|
|
2023
Q3 | $1.8M | Buy |
37,828
+2,115
| +6% | +$161K | ﹤0.01% | 2631 |
|
|
2023
Q2 | $3.42M | Buy |
35,713
+4,020
| +13% | +$437K | ﹤0.01% | 2380 |
|
|
2023
Q1 | $3.59M | Sell |
31,693
-152
| -0.5% | -$16.4K | ﹤0.01% | 2346 |
|
|
2022
Q4 | $3.57M | Buy |
31,845
+692
| +2% | +$92.8K | ﹤0.01% | 2377 |
|
|
2022
Q3 | $4M | Buy |
31,153
+7,584
| +32% | +$777K | ﹤0.01% | 2332 |
|
|
2022
Q2 | $1.62M | Sell |
23,569
-540
| -2% | -$46.5K | ﹤0.01% | 2628 |
|
|
2022
Q1 | $3.43M | Buy |
24,109
+594
| +3% | +$91.4K | ﹤0.01% | 2458 |
|
|
2021
Q4 | $3.92M | Buy |
23,515
+221
| +0.9% | +$35.1K | ﹤0.01% | 2469 |
|
|
2021
Q3 | $3.24M | Buy |
23,294
+2,286
| +11% | +$447K | ﹤0.01% | 2578 |
|
|
2021
Q2 | $10M | Buy |
21,008
+1,889
| +10% | +$797K | ﹤0.01% | 2002 |
|
|
2021
Q1 | $7.87M | Buy |
19,119
+504
| +3% | +$232K | ﹤0.01% | 2079 |
|
|
2020
Q4 | $9.12M | Buy |
18,615
+1,480
| +9% | +$867K | ﹤0.01% | 1922 |
|
|
2020
Q3 | $9.7M | Sell |
17,135
-3,659
| -18% | -$1.22M | ﹤0.01% | 1718 |
|
|
2020
Q2 | $1.98M | Buy |
20,794
+1,321
| +7% | +$116K | ﹤0.01% | 2431 |
|
|
2020
Q1 | $1.39M | Buy |
19,473
+228
| +1% | +$15.3K | ﹤0.01% | 2407 |
|
|
2019
Q4 | $1.33M | Buy |
19,245
+174
| +0.9% | +$12.9K | ﹤0.01% | 2522 |
|
|
2019
Q3 | $1.53M | Buy |
19,071
+5,143
| +37% | +$340K | ﹤0.01% | 2467 |
|
|
2019
Q2 | $897K | Buy |
13,928
+7,153
| +106% | +$679K | ﹤0.01% | 2612 |
|
|
2019
Q1 | $931K | Buy |
6,775
+696
| +11% | +$84.9K | ﹤0.01% | 2573 |
|
|
2018
Q4 | $550K | Sell |
6,079
-46
| -0.8% | -$6.44K | ﹤0.01% | 2732 |
|
|
2018
Q3 | $930K | Buy |
6,125
+262
| +4% | +$42.4K | ﹤0.01% | 2651 |
|
|
2018
Q2 | $1.01M | Buy |
5,863
+928
| +19% | +$152K | ﹤0.01% | 2580 |
|
|
2018
Q1 | $725K | Buy |
4,935
+158
| +3% | +$30.3K | ﹤0.01% | 2622 |
|
|
2017
Q4 | $969K | Sell |
4,777
-387
| -7% | -$79.5K | ﹤0.01% | 2515 |
|
|
2017
Q3 | $1.66M | Buy |
5,164
+587
| +13% | +$160K | ﹤0.01% | 2350 |
|
|
2017
Q2 | $1.03M | Buy |
4,577
+25
| +0.5% | +$5.13K | ﹤0.01% | 2445 |
|
|
2017
Q1 | $1.03M | Buy |
4,552
+222
| +5% | +$45.1K | ﹤0.01% | 2414 |
|
|
2016
Q4 | $858K | Buy |
4,330
+1,200
| +38% | +$262K | ﹤0.01% | 2481 |
|
|
2016
Q3 | $770K | Buy |
3,130
+1,156
| +59% | +$406K | ﹤0.01% | 2470 |
|
|
2016
Q2 | $1.15M | Buy |
1,974
+799
| +68% | +$469K | ﹤0.01% | 2304 |
|
|
2016
Q1 | $624K | Buy |
1,175
+23
| +2% | +$12K | ﹤0.01% | 2491 |
|
|
2015
Q4 | $809K | Buy |
1,152
+371
| +48% | +$244K | ﹤0.01% | 2460 |
|
|
2015
Q3 | $463K | Buy |
+781
| New | +$637K | ﹤0.01% | 2652 |
|
Other funds holding MCRB
FP
LPC
Charles Schwab's MCRB Position: Q2 2026 in Review
Charles Schwab reduced its Seres Therapeutics (MCRB) stake by 1.8% in Q2 2026, selling an estimated $4.42K and leaving 31,049 shares worth $245K. The position accounts for ﹤0.01% of the portfolio, ranked #3354.
Charles Schwab first reported a position in MCRB in Q3 2015 and has held it in 44 quarters since. The position peaked at $10M in Q2 2021. 36 funds tracked by Wall St. Rank hold MCRB as of Q2 2026.
- Charles Schwab held 31,049 shares of Seres Therapeutics worth $245K as of Q2 2026.
- Charles Schwab sold 581 Seres Therapeutics shares in Q2 2026, an estimated $4.42K.
- Seres Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3354 holding.
- Charles Schwab first reported a position in Seres Therapeutics in Q3 2015 and has held it in 44 quarters since.
- Charles Schwab's Seres Therapeutics position peaked at $10M in Q2 2021.
- 36 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.